| Literature DB >> 36078037 |
Rong Wang1,2, Emre Bektik2,3, Phraew Sakon4, Xiaowei Wang1, Shanying Huang1, Xiangbin Meng5, Mo Chen6, Wenqiang Han1, Jie Chen7, Yanhong Wang8, Jingquan Zhong1,9.
Abstract
Atrial fibrillation (AF) is a form of sustained cardiac arrhythmia and microRNAs (miRs) play crucial roles in the pathophysiology of AF. To identify novel miR-mRNA pairs, we performed RNA-seq from atrial biopsies of persistent AF patients and non-AF patients with normal sinus rhythm (SR). Differentially expressed miRs (11 down and 9 up) and mRNAs (95 up and 82 down) were identified and hierarchically clustered in a heat map. Subsequently, GO, KEGG, and GSEA analyses were run to identify deregulated pathways. Then, miR targets were predicted in the miRDB database, and a regulatory network of negatively correlated miR-mRNA pairs was constructed using Cytoscape. To select potential candidate genes from GSEA analysis, the top-50 enriched genes in GSEA were overlaid with predicted targets of differentially deregulated miRs. Further, the protein-protein interaction (PPI) network of enriched genes in GSEA was constructed, and subsequently, GO and canonical pathway analyses were run for genes in the PPI network. Our analyses showed that TNF-α, p53, EMT, and SYDECAN1 signaling were among the highly affected pathways in AF samples. SDC-1 (SYNDECAN-1) was the top-enriched gene in p53, EMT, and SYDECAN1 signaling. Consistently, SDC-1 mRNA and protein levels were significantly higher in atrial samples of AF patients. Among negatively correlated miRs, miR-302b-3p was experimentally validated to suppress SDC-1 transcript levels. Overall, our results suggested that the miR-302b-3p/SDC-1 axis may be involved in the pathogenesis of AF.Entities:
Keywords: RNA sequencing; SYNDECAN-1; atrial fibrillation; atrial fibrosis; heart disease; miR-302; microRNA; transcriptome
Mesh:
Substances:
Year: 2022 PMID: 36078037 PMCID: PMC9454849 DOI: 10.3390/cells11172629
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 7.666
Patient Demographics.
| Group | Age | Gender | Diagnosis | History of AF | Surgery | Site of Sampling |
|---|---|---|---|---|---|---|
| Normal | 60 | Female | Congenital heart disease, atrial septal defect | No AF | Atrial septal repair | Right atrium |
| Normal | 66 | Male | Tricuspid vegetations | No AF | Excision of vegetations | Right atrium |
| AF | 64 | Female | Rheumatic heart disease, mitral stenosis | Persistent AF | Mitral valve replacement | Right atrium |
| AF | 60 | Male | Rheumatic heart disease, mitral stenosis | Persistent AF | Mitral valve replacement | Right atrium |
| AF | 57 | Female | Rheumatic heart disease, mitral stenosis | Persistent AF | Mitral valve replacement | Right atrium |
Figure 1Flowchart of RNA-Seq Experimental and Target Prediction Strategy.
Figure 2miR-Seq analysis for DEGs in the SR control and AF groups. (A) PCA analysis of SR and AF patient samples. (B) The average number of miRs analyzed from patients and the ctrl group in miR-seq. (C) Volcano plot shows significantly upregulated (red), downregulated (blue), and non-significant miRs (grey). Significant miRs are selected based on |log2FoldChange| > 1 and p < 0.05. (D) Heat map matrix shows clustering of differentially expressed miRs between the SR and AF groups. (E) GO and (F) KEGG pathway enrichment analysis of top deregulated pathways.
Top deregulated microRNAs.
| microRNA ID | log2(FoldChange) | |
|---|---|---|
| hsa-miR-302b-3p * | −1.927993099 | 3.52446 × 10−5 |
| hsa-miR-3059-5p * | −2.439099768 | 0.000210321 |
| hsa-miR-302d-3p * | −1.925669264 | 0.000598812 |
| hsa-miR-378d * | −1.1161761 | 0.000863964 |
| hsa-miR-516a-5p * | −2.449280109 | 0.001097802 |
| hsa-miR-302a-5p * | −1.511297201 | 0.001691902 |
| hsa-miR-378i * | −1.038634253 | 0.00180456 |
| hsa-miR-518c-3p * | −3.007366398 | 0.002448495 |
| hsa-miR-516b-5p * | −1.640951948 | 0.002989037 |
| hsa-miR-5708 * | −1.848531157 | 0.003210251 |
| hsa-miR-302a-3p * | −1.884247241 | 0.003340718 |
| hsa-miR-378e | −1.41425312 | 0.004785214 |
| hsa-miR-302c-3p | −2.078986595 | 0.005110454 |
| hsa-miR-517a-3p | −2.146095895 | 0.006125071 |
| hsa-miR-517b-3p | −2.146095895 | 0.006125071 |
| hsa-miR-526b-5p | −4.103564723 | 0.00733209 |
| hsa-miR-371a-3p | −1.330621285 | 0.01025266 |
| hsa-miR-520g-3p | −1.89787358 | 0.01062743 |
| hsa-miR-585-3p | −1.925975099 | 0.01506384 |
| hsa-miR-372-3p | −1.232670652 | 0.015762249 |
| hsa-miR-4662a-5p | −1.128104683 | 0.016532088 |
| hsa-miR-378h | −1.380015786 | 0.018242992 |
| hsa-miR-520c-3p | −1.84779246 | 0.028579751 |
| hsa-miR-523-3p | −2.295223982 | 0.039597527 |
| hsa-miR-520a-3p | −1.640624273 | 0.03967688 |
| hsa-miR-519a-5p | −2.207467024 | 0.04264619 |
| hsa-miR-1323 | −2.430852745 | 0.045529514 |
| hsa-miR-520f-3p | −1.351910815 | 0.046170691 |
| hsa-miR-520b-3p | −2.29949029 | 0.047158202 |
| hsa-miR-1323 | −2.430852745 | 0.045529514 |
| hsa-miR-146b-5p * | 2.347289373 | 7.56934 × 10−9 |
| hsa-miR-146b-3p * | 2.289327335 | 2.21466 × 10−7 |
| hsa-miR-155-5p * | 1.274620071 | 0.00071305 |
| hsa-miR-3690 * | 1.641664997 | 0.004215924 |
| hsa-miR-187-5p * | 1.844437031 | 0.011552148 |
| hsa-miR-187-3p * | 1.028719714 | 0.013972754 |
| hsa-miR-592 * | 3.091036819 | 0.023513587 |
| hsa-miR-212-3p * | 1.148408853 | 0.024049925 |
| hsa-miR-549a-3p * | 2.91790048 | 0.026012753 |
* Top selected miRs for constructing a regulatory network of miR–gene pairs.
Figure 3mRNA-seq analysis for DEGs in the SR control and AF groups. (A) PCA analysis of SR and AF patient samples. (B) The average number of genes analyzed from patients and the ctrl group in mRNA-seq. (C) Volcano plot shows significantly upregulated (red), downregulated (blue), and non-significant (grey) genes. Significant genes are selected based on |log2(FoldChange)| > 1 and p < 0.05. (D) Heat map shows clustering of differentially expressed genes between the SR and AF groups. (E) GO and (F) KEGG pathway enrichment analysis of top deregulated pathways.
Figure 4Analysis of upregulated genes and selection of candidate miR–mRNA pairs. (A) Gene-set enrichment analysis (GSEA) of upregulated genes. (B) Enrichment plots of some of the top enriched pathways. (C) Heat map showing top 50 positively enriched genes in GSEA based on enrichment score. (D) Venn diagram showing overlapping genes between top 50 positively enriched genes in GSEA (blue) and all predicted targets of top 11 downregulated miRs in RNA-seq (red). A total of 9 overlapping genes between groups were selected as potential candidates and their enrichment scores and log2(FoldChanges) are listed in the table. (E) Interaction network of positively enriched genes in GSEA and their negatively correlated microRNAs.
Overlapping genes between predicted targets of top 11 downregulated miRs and top 50 positively enriched genes in GSEA.
| Gene Name | NCBI_GI | Rank among Top 50 Upregulated Genes | miRNA ID | Rank among Downregulated miRs | miRDB Target Score (Out of 100) |
|---|---|---|---|---|---|
| FAM72A | 729533 | 1 | hsa-miR-3059-5p | 2 | 67 |
| KYAT1 | 883 | 3 | hsa-miR-302a-5p | 6 | 51 |
| LRRC38 | 126755 | 4 | hsa-miR-516b-5p | 9 | 50 |
| SDC1 | 6382 | 8 | hsa-miR-302b-3p | 1 | 96 |
| hsa-miR-302d-3p | 3 | 96 | |||
| hsa-miR-302a-3p | 11 | 96 | |||
| PTCHD4 | 442213 | 9 | hsa-miR-3059-5p | 2 | 93 |
| TYW1B | 441250 | 10 | hsa-miR-3059-5p | 2 | 77 |
| FCER2 | 2208 | 21 | hsa-miR-516b-5p | 9 | 82 |
| SELE | 6401 | 31 | hsa-miR-3059-5p | 2 | 65 |
| FBXL16 | 146330 | 35 | has-miR-3059-5p | 2 | 63 |
Figure 5Analysis of downregulated genes and selection of candidate miR–mRNA pairs. (A) Gene-set enrichment analysis (GSEA) of downregulated genes. (B) Enrichment plots of some of the top enriched pathways. (C) Heat map showing top 50 negatively enriched genes in GSEA based on enrichment score. (D) Venn diagram showing overlapping genes between top 50 negatively enriched genes in GSEA (blue) and all predicted targets of top 9 upregulated miRs in the RNA-seq dataset (red). A total of six overlapping genes between groups were selected as potential candidates and their enrichment scores and log2(FoldChanges) are listed in the table. (E) Interaction network of negatively enriched genes in GSEA and their negatively correlated miRs.
Overlapping genes between predicted targets of top 9 upregulated miRs and top 50 negatively enriched genes in GSEA.
| Gene Name | NCBI_GI | Rank among Top 50 Downregulated mRNAs | miRNA ID | Rank among Upregulated miRs | miRDB Target Score (Out of 100) |
|---|---|---|---|---|---|
| FERMT1 | 55612 | 4 | hsa-miR-549a-3p | 9 | 67 |
| SLC36A2 | 153201 | 7 | hsa-miR-187-3p | 6 | 57 |
| GPM6B | 2824 | 25 | hsa-miR-146b-5p | 1 | 86 |
| hsa-miR-155-5p | 3 | 82 | |||
| hsa-miR-3690 | 4 | 80 | |||
| CCNI2 | 645121 | 29 | hsa-miR-592 | 7 | 57 |
| MCTP2 | 55784 | 39 | hsa-miR-146b-5p | 1 | 78 |
| GUCY1A2 | 2977 | 50 | hsa-miR-187-5p | 5 | 76 |
Figure 6Validating expression of miR-302b-3p and SDC-1 in human atrial tissue. (A,B) Expression of SDC-1 (A) mRNA (n = 6) and (B) protein (n = 3) in SR (sinus rhythm) vs. AF atrial tissue samples. (C) Expression levels of miR-302 family in atrial tissue samples of the SR vs. AF groups (n = 6). ** p < 0.01 or *** p < 0.005.
Figure 7miR-302-3p may regulate atrial fibrosis by targeting the expression of SDC-1. (A) Conserved sequences of miR-302 family. Underlined sequences indicate conserved nucleotides including their seed sequences. Seed sequences were highlighted in red capital letters. (B) Transfection of negative ctrl (NC) (n = 4) vs. mimics of miR-302a-3p (n = 6), miR-302b-3p (n = 6), or miR-302d-3p (n = 4) into 293T cells. (C) qRT-PCR shows SDC-1 gene expression levels after transfection with NC (n = 6) or miR mimics (n = 4). (D) Luciferase assay for the mutant and wild-type 3’UTR of SDC-1 following transfection with control or miR-302b-3p mimics (n = 3). (E) Reduced SDC-1 levels in human dermal fibroblasts (HDF) transfected with miR-302b-3p mimics (n = 4) (F) Immunohistochemistry of SDC-1 in atrial tissues samples from SR (sinus rhythm) control and AF patients (G) Picrosirius red staining of collagen fibers in SR ctrl and AF patients. Total collagen appears in dark pink color (left column) with standard light microscopy. Collagen-I appears in red (right panel) with polarized light microscopy. * p < 0.05 or ** p < 0.01.
Figure 8Proposed mechanism of SDC-1 in fibrotic remodeling of AF. Decreased levels of the miR-302-3p family will result in increased expression of SYNDECAN-1 in atrial cardiac fibroblasts, which will stimulate TGF-β/Smad2-mediated atrial fibrosis.